

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)(10) International Publication Number
WO 2022/175414 A9

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/30 (2006.01)
 A61K 35/17 (2015.01) C07K 16/32 (2006.01)
 C07K 16/28 (2006.01) C07K 16/40 (2006.01)
 C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/EP2022/054011

(22) International Filing Date:

17 February 2022 (17.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2102224.9 17 February 2021 (17.02.2021) GB
 2111685.0 14 August 2021 (14.08.2021) GB

(71) Applicants: GAMMADELTA THERAPEUTICS LTD

[GB/GB]; 1 Kingdom Street, London, W2 6BD (GB).
F-STAR THERAPEUTICS LIMITED [GB/GB]; Edde-
 va B920, Babraham Research Campus, Cambridge, Cam-
 bridgeshire, CB22 3AT (GB).

(72) **Inventors:** TUNA, Mihriban; c/o Adaptate Biotherapeu-
 tics Ltd., WestWorks, 195 Wood Lane, White City Place,
 London W12 7FQ (GB). UDEN, Mark; c/o Adaptate Bio-
 therapeutics Ltd., WestWorks, 195 Wood Lane, White City
 Place, London W12 7FQ (GB). FREEDMAN, Joshua; c/
 o Adaptate Biotherapeutics Ltd., WestWorks, 195 Wood
 Lane, White City Place, London W12 7FQ (GB). MOUNT,
 Natalie; c/o Adaptate Biotherapeutics Ltd., WestWorks,
 195 Wood Lane, White City Place, London W12 7FQ (GB).

(74) **Agent:** HEATH, Abigail; Kilburn & Strode LLP, Lacon
 London, 84 Theobalds Road, London WC1X 8NL (GB).

(81) **Designated States** (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
 KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
 NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
 RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
 ZW.

(84) **Designated States** (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
 contained color or greyscale and is available for download
 from PATENTSCOPE

(48) Date of publication of this corrected version:

15 June 2023 (15.06.2023)

(15) Information about Correction:

see Notice of 15 June 2023 (15.06.2023)

(54) **Title:** MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES

(57) **Abstract:** The present invention provides multispecific antibodies comprising a Fab region and an Fc region, wherein the Fab region comprises a binding site specific for an epitope of the variable delta 1 (V δ 1) chain of a $\gamma\delta$ T cell receptor (TCR); and the Fc region comprises an EGFR binding site. The present invention also provides compositions and pharmaceutical compositions comprising such multispecific antibodies, and method of making such multispecific antibodies. The present invention also provides methods of treatment and medical uses involving the multispecific antibodies.